ArticleChinese journal of cancer2014
High-grade gliomas: reality and hopes.
Article in Chinese journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect.Medical physics · 2026Article
- circRNA-SMO upregulates CEP85 to promote proliferation and migration of glioblastoma via sponging miR-326.Histology and histopathology · 2023Article
- Preoperative Systemic Immune-Inflammation Index is a Potential Biomarker in Adult Patients with High-Grade Gliomas Undergoing Radical Resection.Journal of inflammation research · 2023Article
- Role of autophagy in regulation of glioma stem cells population during therapeutic stress.Journal of stem cells & regenerative medicine · 2020Article
- Circular RNA SMO sponges miR-338-3p to promote the growth of glioma by enhancing the expression of SMO.Aging · 2019Article
- KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.OncoTargets and therapy · 2018Article
- SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.Oncotarget · 2017Article
- Anti-tumoral activity of native compound morelloflavone in glioma.Oncology letters · 2016Article
- Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy.Molecular and clinical oncology · 2016Article
- Methylation of the miR-126 gene associated with glioma progression.Familial cancer · 2016Article
- Myosin VI contributes to malignant proliferation of human glioma cells.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2016Article
- MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.American journal of cancer research · 2016Article
- Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma.Oncogene · 2015Article
- Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Genes & diseases · 2015Article
- Combination of unsaturated fatty acids and ionizing radiation on human glioma cells: cellular, biochemical and gene expression analysis.Lipids in health and disease · 2014Article
- MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.BMC cancer · 2014Article
- Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of the Chinese Journal of Cancer, European experts review current standards, trends, and future prospects in the difficult domain of high-grade glioma. In all fields covered by the different authors, the progress has been impressive. For example, discoveries at the molecular level have already impacted imaging, surgery, radiotherapy, and systemic therapies, and they are expected to play an increasing role in the management of these cancers. The European Organization for Research and Treatment of Cancer (EORTC) has pioneered new treatment strategies and contributed to new standards. The articles in this issue will cover basic molecular biological principles applicable today, novel surgical approaches, innovations in radiotherapy planning and delivery, evidence-based standards for radiotherapy alone or combined with chemotherapy, current standards and novel approaches for systemic treatments, and the important but often neglected field of health-related quality of life. Despite the advances described in these articles, the overall prognosis of high-grade glioma, especially glioblastoma, remains poor, and more research is needed to address this problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.